Northwire Canada EditionWednesday, July 15, 2026
Sign inSubscribe
Northwire
⌕
EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0% EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0%
Other

Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals

By The Northwire Desk — AI Analysis Feb 12, 2026 · 03:45 4565 · None None
4565 · Price

Executive Summary

  • Centessa Pharmaceuticals achieved an early development milestone for its OX2R agonist ORX489, triggering a $1.8 million payment to Nxera Pharma under their research collaboration.
  • The $1.8 M milestone will be recognized as revenue in Nxera’s first quarter of 2026, providing a material positive impact on the company’s near‑term financial results.
  • The announcement underscores progress in Nxera’s partnership pipeline and highlights ongoing development of neuropsychiatric disorder therapeutics.

Key Details

  • Milestone Achievement: Early development milestone for Centessa’s investigational oral OX2R agonist, ORX489 (targeting neuropsychiatric disorders).
  • Payment Amount: US$1.8 million payable to Nxera Pharma upon milestone completion.
  • Revenue Recognition: The payment will be recorded as revenue in Nxera’s Q1 2026 financial statements.
  • Collaboration Context: Payment is pursuant to the existing research collaboration agreement between Nxera Pharma and Centessa Pharmaceuticals.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from None

Jun 30, 2026 · 04:27

AI-driven GPCR drug discovery platform monetizing partnerships while transitioning to a profitable specialty pharma model in APAC.

Other Jun 10, 2026 · 02:35

AI-driven GPCR drug discovery platform accelerates pipeline through strategic consortium membership and milestone-driven revenue turnaround.

M&A / Property Jun 01, 2026 · 19:30

Nxera Accelerates Vamorolone Rollout in South Korea as APAC Specialty Pharma Strategy Gains Traction

Regulatory May 11, 2026 · 02:34

GPCR spin-out reels in $275M in biobucks and equity, keeping Asia rights and cash burn in check

M&A / Property May 08, 2026 · 06:26

Nxera Pharma Defends Core IP Amidst Profitability Turnaround

Regulatory May 01, 2026 · 02:36

Nxera Pharma Turns Profitable on Milestone Surge, But Cash Burn Raises Liquidity Questions

Earnings